---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-040825"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:19:10.671440+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia cuts FY2021 NUPLAZID revenue guidance to $480-515M; FDA reiterates need for additional DRP studies

## Summary
- 2Q21 net sales $115.2M (+5% YoY); net loss $43.9M ($0.27/share) vs $42.1M loss in 2Q20.
- FY2021 revenue guidance reduced to $480-515M from $510-550M due to pandemic and higher gross-to-net (~20%).
- FDA Type A meeting on pimavanserin for DRP: FDA insists on additional studies per subgroup but open to further discussion.
- GAAP R&D guidance lowered to $250-270M (prior $280-300M); SG&A guidance unchanged at $385-415M.
- Phase 3 LAVENDER (trofinetide for Rett syndrome) top-line expected Q4 2021; Phase 2 ACP-044 pain results also Q4 2021.

## SEC filing metadata
- accession: 0001564590-21-040825
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000156459021040825/0001564590-21-040825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000156459021040825/acad-8k_20210804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-040825
- JSON: https://secwatch.observer/filing/0001564590-21-040825.json
- Plain text: https://secwatch.observer/filing/0001564590-21-040825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.